CLINICAL_TRIALS ClinicalTrials.gov record update

Ivonescimab (PD-1/VEGF Bispecpecial Antibody) in the Treatment of Multiple Advanced Tumors: a Multi-cohort, Multi-center, Single-arm Phase II Study

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06683846
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:24.867619+00:00
Published At: 2025-08-24T00:00:00+00:00
Record Updated At: 2025-08-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Pheochromocytoma/Paraganglioma", "Rhabdomyosarcoma", "Paget Disease, Extramammary", "Renal Angiomyolipoma", "Perivascular Epithelioid Cell Tumor, Malignant", "Sarcoma", "Urachal Cancer", "Neuroendocrine Cancer", "Basal Cell Carcinomas", "Sarcomatoid Carcinoma", "Penile Cancer", "Adrenal Cortical Cancer", "Germ Cell Cancer Metastatic", "Non-Clear Cell Renal Cell Carcinoma", "Prostate Cancers", "Clear Cell Renal Cancer", "Urothelial Carcinoma", "Kidney Cancer", "Rare Tumors"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-24"
protocolSection.identificationModule.nctId: "NCT06683846"
protocolSection.identificationModule.officialTitle: "Ivonescimab (PD-1/VEGF Bispecpecial Antibody) in the Treatment of Multiple Advanced Tumors: a Multi-cohort, Multi-center, Single-arm Phase II Study"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.